Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.37 |
| ▸ | HTR7 | P34969 | 4/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488222 | 0.99 | DRD3 (0.41) | DRD3HRH2HRH1GAASIGMAR1 | |
| SCHEMBL6496563 | 0.78 | ALDH1A1 (0.56) | HRH2HRH1GAAALDH1A1 | |
| SCHEMBL6485200 | 0.77 | KDM4E (0.41) | HRH2HRH1SIGMAR1ALDH1A1 | |
| SCHEMBL6484741 | 0.77 | KDM4E (0.41) | HRH2HRH1SIGMAR1ALDH1A1 | |
| SCHEMBL6487284 | 0.75 | KDM4E (0.41) | HRH2HRH1SIGMAR1ALDH1A1 | |
| SCHEMBL4005408 | 0.73 | ACHE (0.49) | ALDH1A1 | |
| SCHEMBL18476170 | 0.73 | HRH2 (0.54) | DRD3HRH2HRH1 | |
| SCHEMBL4330983 | 0.71 | ACHE (0.46) | ALDH1A1 | |
| SCHEMBL22521105 | 0.71 | HRH2 (0.56) | DRD3HRH2HRH1HTR7HTR1A | |
| SCHEMBL24773181 | 0.70 | HRH2 (0.53) | DRD3HRH2HRH1GAASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861432-B2 | Piperazine derivatives that destabilize androgen receptors | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-01 | — | — | US | claimed |
| US-20040009969-A1 | Piperazine derivatives that destabilize androgen receptors | SCHERING AG (DE) | 2004-01-15 | — | — | US | claimed |
| US-6861432-B2 | Piperazine derivatives that destabilize androgen receptors | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009969-A1 | Piperazine derivatives that destabilize androgen receptors | AR, FSHR, GNRHR | DRD3 657/4885HRH2 1226/4885HRH1 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.